Addyi Black / African Ancestry Safety Profile Differences

What the Key Trials Actually Showed About Race and Ethnicity

The five Phase III flibanserin RCTs that supported FDA approval enrolled predominantly White participants, which limits direct race-stratified efficacy conclusions. The BEGONIA trial (N=949) published in the Journal of Sexual Medicine in 2014 is the largest single study [1]. Across pooled trial data, Black and African American women represented roughly 8 to 10% of enrollees, a proportion too small for adequately powered subgroup analysis.

Efficacy Signal in Minority Subgroups

FDA's 2015 advisory committee briefing document noted that the overall pooled treatment effect, roughly 0.5 additional satisfying sexual events per month above placebo and a 0.6-point improvement on the Female Sexual Distress Scale-Revised (FSDS-R), was not disaggregated by race in the primary publications [2]. The absence of a statistically significant interaction term for race does not confirm equivalence. It reflects underpowering.

Clinicians should interpret this as: there is no positive evidence of differential efficacy by ancestry, and no negative evidence either. The honest answer is that the data are insufficient.

Placebo Response Rates and Their Relevance

Placebo response rates in HSDD trials run high, averaging around 30 to 40% improvement on distress scales [3]. Socioeconomic and cultural determinants of sexual well-being, which do vary by race and structural access to care, can inflate or suppress placebo response. A 2021 analysis in the Journal of Sexual Medicine found that women from racial minority groups reported higher baseline distress scores and somewhat higher placebo responses in pain and sexual function trials, though flibanserin-specific data were not separated [4].

CYP2C19 Pharmacogenomics and Why Ancestry Matters

Flibanserin is metabolized primarily by CYP3A4 and secondarily by CYP2C19 [5]. Genetic variation in CYP2C19 alters plasma drug exposure and may shift the hypotension and CNS depression risk profile.

CYP2C19 Allele Frequencies Across Ancestries

The CYP2C19*2 loss-of-function allele, the most common cause of poor-metabolizer status, occurs at a frequency of approximately 15% in African populations compared with 12 to 15% in European populations, based on PharmGKB population frequency data [6]. That difference is modest. The more clinically consequential variation involves CYP2C19*17, a gain-of-function (ultrarapid metabolizer) allele present at ~16 to 21% frequency in African populations versus ~18 to 21% in European populations [6].

What Poor-Metabolizer Status Means for Flibanserin Exposure

A CYP2C19 poor metabolizer taking flibanserin 100 mg nightly will accumulate higher plasma flibanserin concentrations than an extensive metabolizer. The FDA label reports that CYP2C19 poor metabolizers show approximately a 1.8-fold increase in flibanserin AUC compared to extensive metabolizers [2]. Higher AUC directly translates to a steeper hypotension and sedation risk curve, particularly if even modest alcohol ingestion occurs.

Population pharmacokinetic modeling published in the CPT: Pharmacometrics and Systems Pharmacology journal confirms that CYP2C19 genotype, combined with CYP3A4 inhibitor co-administration, produces the largest clinically meaningful increases in flibanserin exposure [7].

Practical Genotyping Guidance

Routine pretreatment CYP2C19 genotyping is not currently mandated by the FDA label or REMS program [2]. However, the Clinical Pharmacogenomics Implementation Consortium (CPIC) has published CYP2C19 guidelines for other CNS-active drugs such as clopidogrel and tricyclic antidepressants [8]. If a patient of any ancestry has previously undergone pharmacogenomic panel testing, reviewing CYP2C19 status before initiating flibanserin is a low-effort, high-yield step.

A practical prescribing framework for CYP2C19-aware flibanserin initiation:

1. Review any existing PGx panel results for CYP2C19 star allele status.
2. If the patient is a confirmed poor metabolizer, counsel on amplified hypotension risk and reinforce zero-alcohol guidance with extra emphasis.
3. Screen for concurrent moderate or strong CYP3A4 inhibitors (fluconazole, clarithromycin, combined oral contraceptives containing certain progestins), each further elevates flibanserin AUC [2].
4. Document cardiovascular baseline (blood pressure, resting heart rate) before the first prescription.
5. Reassess at 8 weeks; discontinue if no improvement in satisfying sexual events or FSDS-R score.

Cardiovascular Comorbidity Burden in Black Adults

This section addresses the practical safety overlay that arises from population-level cardiovascular health disparities, not from any intrinsic biological difference.

Hypertension Prevalence

CDC surveillance data show that 57% of non-Hispanic Black adults in the United States have hypertension, compared with 43% of non-Hispanic White adults [9]. Flibanserin's most serious acute risk is orthostatic hypotension and syncope, risk that is compounded when antihypertensive medications are co-administered [2]. The FDA label specifically warns that blood-pressure-lowering drugs can potentiate flibanserin's hypotensive effect.

Antihypertensive Drug Interactions

Black patients with hypertension are more frequently managed with calcium channel blockers and thiazide diuretics as first-line agents, consistent with JNC-8 and ACC/AHA 2017 guideline recommendations for this population [10]. Calcium channel blockers such as amlodipine are moderate CYP3A4 inhibitors at higher doses. Diltiazem and verapamil are strong CYP3A4 inhibitors and carry an explicit contraindication with flibanserin in the FDA label [2].

A patient taking verapamil for rate control and flibanserin 100 mg nightly is at substantially higher risk for acute hypotensive syncope. This interaction is not theoretical. The FDA 2015 approval briefing document documented a case series of syncope events in flibanserin-treated women taking CYP3A4 inhibitors [2].

Chronic Kidney Disease Considerations

Black adults develop CKD at approximately 3.7 times the rate of White adults, driven largely by hypertension, diabetes, and APOL1 risk variant prevalence [11]. Flibanserin is not renally cleared to a meaningful degree (the primary route is hepatic), but CKD-associated polypharmacy increases the probability of CYP3A4 or CYP2C19 interaction exposure. A nephrologist or clinical pharmacist medication review is advisable before initiating flibanserin in a patient with stage 3b or higher CKD.

G6PD Deficiency: An Underappreciated Consideration

G6PD deficiency affects approximately 10 to 15% of males of African ancestry and a smaller but clinically relevant percentage of females who are heterozygous carriers [12]. Flibanserin's FDA label does not list G6PD deficiency as a contraindication or warning. The drug's chemical structure is a benzimidazole derivative, and benzimidazole-class compounds have not been systematically studied in G6PD-deficient populations.

Why This Warrants Attention

G6PD-deficient patients are at risk for drug-induced hemolytic anemia from oxidative stressors. Flibanserin has not been directly implicated in oxidative hemolysis, and no published case reports document this interaction. The concern is precautionary: in the absence of G6PD-specific safety data, clinicians should note G6PD status in the chart and monitor for signs of hemolysis (fatigue, jaundice, dark urine) in the first 4 to 8 weeks of therapy.

The American Society of Hematology provides screening guidance for G6PD testing in at-risk populations [13]. Testing is inexpensive and available through standard labs.

The REMS Program and Its Implications for Minority Patients

The FDA ADDYI REMS program requires that both prescribers and pharmacies be certified before flibanserin can be dispensed [2]. Prescribers must counsel patients on the alcohol contraindication and the risk of hypotension and syncope.

Access Disparities

REMS certification requirements, though medically warranted, create access friction. A 2020 JAMA Internal Medicine study on REMS programs for reproductive health medications found that pharmacy certification gaps were more pronounced in predominantly minority and lower-income zip codes [14]. Patients of Black ancestry may therefore face greater practical barriers to filling a flibanserin prescription than their White counterparts, a structural disparity unrelated to pharmacology.

Clinicians should identify a REMS-certified pharmacy near the patient before writing the prescription. The FDA's REMS database is searchable at fda.gov [2].

Alcohol Counseling in Context

The absolute contraindication to alcohol is the most frequently cited barrier to flibanserin adherence. Alcohol use disorder affects approximately 5.8% of Black adults according to SAMHSA 2022 data [15]. Screening with a validated tool such as the AUDIT-C before initiating flibanserin is standard practice and is specifically recommended by the REMS prescriber training module.

HSDD Diagnosis in Black Women: Underdiagnosis and Cultural Factors

HSDD is underdiagnosed across all populations, but culturally rooted barriers to discussing sexual health with providers compound the problem for Black women specifically. A 2019 study in the Journal of Women's Health found that Black women were significantly less likely than White women to have sexual dysfunction discussed by their clinician during a routine visit, even after controlling for visit type and insurance [16].

Validated Diagnostic Tools

The Female Sexual Function Index (FSFI) and the FSDS-R are validated across racial groups, though normative data were largely developed in majority-White samples [17]. Clinicians should interpret borderline FSFI domain scores in the context of relationship, cultural, and contextual factors rather than applying a rigid numeric cutoff.

Psychological and Pharmacological Overlap

The FDA label notes that flibanserin is not indicated for postmenopausal women or for HSDD attributable to a medical condition, relationship problem, or medication side effect [2]. Depression disproportionately affects Black women who face chronic stress related to structural racism. SSRIs and SNRIs, commonly used to treat depression, independently cause sexual dysfunction and may be the proximate cause of low desire rather than primary HSDD [18]. Prescribing flibanserin on top of an SSRI without addressing the SSRI contribution is not appropriate.

The 2014 BEGONIA trial did not stratify outcomes by concurrent antidepressant use. Clinicians should evaluate whether dose reduction or switching to bupropion (which carries lower sexual side-effect burden) addresses the low-desire complaint before reaching for flibanserin [1].

Hepatic Metabolism and Alcohol: The Core Safety Mechanism

Flibanserin is heavily hepatically metabolized. The drug's interaction with alcohol is not simply pharmacodynamic CNS additive sedation. It involves shared CYP2E1 metabolic competition that elevates plasma flibanserin concentrations acutely [2].

Alcohol-Flibanserin Interaction Study Data

The FDA required a dedicated alcohol interaction study before approval. In that crossover study (N=25), co-ingestion of alcohol with flibanserin produced severe hypotension and syncope in a subset of participants, with systolic blood pressure dropping to values below 90 mmHg in some cases [2]. The study was terminated early due to the severity of events.

Liver Disease Contraindication

Flibanserin is contraindicated in patients with hepatic impairment of any severity [2]. Non-alcoholic fatty liver disease (NAFLD) prevalence is rising across all populations. Data from the American Association for the Study of Liver Diseases estimate NAFLD prevalence at 24% globally [19]. Clinicians should confirm normal hepatic function with AST, ALT, and bilirubin before initiating therapy.

Drug-Drug Interactions Most Likely in This Population

Beyond CYP3A4 and CYP2C19, several drug categories warrant specific attention in patients of Black ancestry given prescribing patterns driven by comorbidity burden.

Antifungals

Fluconazole, a strong CYP3A4 and CYP2C19 inhibitor, is explicitly contraindicated with flibanserin [2]. Recurrent vaginal candidiasis, which has higher reported prevalence in Black women partly due to higher rates of diabetes and antibiotic exposure, means fluconazole prescriptions are common in this group. Temporary suspension of flibanserin during a fluconazole course (and for 2 days after the last fluconazole dose) is required by the label.

HIV Antiretrovirals

Black Americans account for 40% of new HIV diagnoses in the United States [20]. Several antiretroviral regimens include ritonavir-boosted or cobicistat-boosted drugs, which are among the most potent CYP3A4 inhibitors available. Co-administration with flibanserin is contraindicated. Clinicians must review the full antiretroviral regimen before prescribing.

Hormonal Contraceptives

Combined oral contraceptives containing ethinyl estradiol can weakly inhibit CYP3A4. The FDA label reports a modest flibanserin AUC increase with OC co-administration, insufficient to trigger a contraindication but sufficient to recommend reinforcing alcohol abstinence counseling [2].

Monitoring Protocol for Flibanserin in Higher-Risk Patients

For patients of Black or African ancestry who have one or more of the comorbidities or drug interactions described above, the following monitoring approach is appropriate.

Baseline Assessment

• Blood pressure and heart rate (seated and standing to evaluate orthostatic response).
• Hepatic function panel (AST, ALT, total bilirubin).
• Review of full medication list for CYP3A4 and CYP2C19 inhibitors or inducers.
• AUDIT-C alcohol screen.
• G6PD status if not previously documented (especially relevant for female patients from West African ancestry with a family history of G6PD deficiency in male relatives).

Follow-Up at 4 and 8 Weeks

Reassess blood pressure. Ask specifically about dizziness, near-syncope, or syncope episodes. Confirm continued alcohol abstinence. Assess FSDS-R score; discontinue if no clinically meaningful improvement by 8 weeks, consistent with the FDA label's guidance [2].

A mean improvement of at least 1 point on the FSDS-R or at least 0.5 additional satisfying sexual events per month is the threshold used in the key trials to define a responder [1].

Synthesizing the Evidence: What Clinicians Should Take Away

No trial has demonstrated that flibanserin works differently in Black or African ancestry patients as a direct pharmacological matter. The safety considerations that differ by ancestry are real but arise from three layers: (1) population differences in CYP2C19 allele frequencies that modestly shift drug exposure; (2) higher prevalence of comorbidities (hypertension, CKD, HIV) that create drug-interaction exposure; and (3) structural access disparities affecting REMS pharmacy availability and clinical follow-up.

"The absence of evidence of harm is not evidence of absence of harm," as stated in the 2015 FDA advisory committee transcript on flibanserin [2]. Ethnicity-stratified safety data for flibanserin remain a gap in the published literature. Until dedicated pharmacogenomic and subgroup studies are conducted in adequately powered samples of Black women, individualized risk assessment remains the standard of care.

Prescribers should complete the ADDYI REMS certification, confirm hepatic function is normal, screen for CYP3A4/2C19 inhibitor co-medications, document blood pressure at baseline, and schedule a follow-up visit at 8 weeks to evaluate both efficacy and safety before continuing therapy.